FY2027 Earnings Forecast for IOVA Issued By Zacks Research

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings per share estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria expects that the biotechnology company will earn $0.13 per share for the year. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share.

A number of other equities analysts have also weighed in on the company. Chardan Capital decreased their target price on Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Friday, February 28th. Piper Sandler cut their price target on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a research note on Friday, February 28th. Robert W. Baird lowered their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Friday, February 28th. Finally, The Goldman Sachs Group cut their target price on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $20.25.

Remove Ads

Iovance Biotherapeutics Trading Down 4.1 %

Shares of IOVA traded down $0.15 during mid-day trading on Friday, reaching $3.48. 6,270,313 shares of the stock traded hands, compared to its average volume of 6,980,526. Iovance Biotherapeutics has a 1 year low of $3.42 and a 1 year high of $15.18. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -2.34 and a beta of 0.93. The firm has a fifty day moving average price of $5.03 and a 200 day moving average price of $7.66.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million for the quarter, compared to analysts' expectations of $72.17 million.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in IOVA. California State Teachers Retirement System lifted its stake in shares of Iovance Biotherapeutics by 7.3% in the 4th quarter. California State Teachers Retirement System now owns 203,241 shares of the biotechnology company's stock valued at $1,504,000 after acquiring an additional 13,774 shares during the last quarter. Arcadia Wealth Management Inc. purchased a new position in Iovance Biotherapeutics in the 4th quarter worth approximately $117,000. B. Riley Wealth Advisors Inc. lifted its position in Iovance Biotherapeutics by 39.4% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 19,442 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 5,500 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Iovance Biotherapeutics during the fourth quarter valued at approximately $47,000. Finally, Neo Ivy Capital Management purchased a new stake in shares of Iovance Biotherapeutics during the fourth quarter valued at approximately $3,353,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.